Last updated 18:35:02
HK$47.20
+220.00%
- Listing price
- HK$14.75
- Open
- —
- High
- —
- Low
- —
- Bid / Ask
- — / —
- Volume
- —
Turnover —View source
CF PHARMTECH
02652Listed醫療健康 · CF PharmTech, Inc.是一家在中国注册成立的股份有限公司，主要从事药品研发、生产和销售。
CF PHARMTECH (長風藥業) (02652) is a listed Hong Kong IPO. This page brings together the offer price, entry fee, subscription timeline, grey-market context, allotment data and stage-based reference research in one place.
- Offer price
- HK$14.75
- Final offer price
- HK$14.75
- One-lot win rate
- 1.0%
- Proceeds
- HK$607.7M
- Public oversub.
- 6697.8x
Predicted 1.0%
Lot / entry fee 500 shares · HK$7K · Sponsor CITIC Securities / CMB International
- Offer starts Sep 26
- /Offer closes Oct 2
- /Grey market Oct 6
- /Listing Oct 8Now
SubscriptionCF PHARMTECH: subscription-stage reference
The subscription stage draws on the prospectus, sponsor record and early public filings. Allotment results and grey-market prints have not occurred yet.
Earlier stage- Reference rating
- High attention
- Reference score
- 75.7
- Forecast grey range
- +17.5% – +99.2%
Pre-greyCF PHARMTECH: pre-grey-market reference
The pre-grey stage includes published allotment and public oversubscription data. Grey-market prints are not yet reflected here.
Earlier stage- Reference rating
- High attention
- Reference score
- 79.4
- Forecast grey range
- +17.2% – +98.4%
Post-greyCF PHARMTECH: post-grey-market reference
The post-grey stage includes grey-market price and turnover observations. Listing-day results still follow official trading and company announcements.
Current- Reference rating
- High attention
- Reference score
- 82.7
- Forecast first-day range
- +210.9% – +274.8%
View factors and research
Model forecastListing-day trendStrong positiveUp probability 85.1%
Published outcome check
First-day resultBig up+161.0%
Our call: Trend call valid
Covered 16/25 core factors
UsedMissingNot yet scorableN/A
Margin oversubscription
High heatOffer size
Good qualityCornerstone lockup
—Post-lockup offer value
—Recent same-rule trend
Strong trendRecent same-type trend
Strong trendRecent sector trend
Strong trendValuation
Average appealFundamental quality
Average qualityGrowth quality
Weak qualityProfitability
Weaker qualityCash runway
Weak qualityCustomer concentration
—Cornerstone quality
—Sponsor record
Strong recordGreenshoe arrangementNo greenshoe
Stabilizer track record
—A-share pre-grey trend
—A-share listing-day trend
—Public oversubscription
High heatOne-lot win rate
High heatInternational placing
High heatFinal pricing position
—Actual greenshoe use
—Grey market return
Strong trendThe assessment and probability ranges are informational only and are not investment advice.
AI Research Report
Post-greyThe analysis report for this IPO is being generated.
CF PHARMTECH: grey-market trend
CF PHARMTECH: predicted allotment
Only key tiers are shown here. Full tiers and other allotment-pattern comparisons are on the allotment-odds page.
- 1 lot
- 1.0%
- A tail · Apply 600 lots
- 0.07 lots
- B head · Apply 800 lots
- 0.11 lots
- Top hammer
- 0.16 lots
Predicted
Official
1.0%
Predicted
Official
0.05 lots
Predicted
Official
0.08 lots
Predicted
Official
0.43 lots
Most likely allotment pattern：Larger Pool A applications get less extra allotment；Pool B high-tier allotment drops quicklyView full allotment-odds research
How to read this page
These answers combine this IPO’s published figures with clearly labeled model estimates. They explain how to read the modules above and are not investment advice.
What is the one-lot allotment rate for CF PHARMTECH?
Public allotment filings put the official one-lot rate at 1.0%, versus this site's pre-allotment model estimate of 1.0%. It is an observation for a 1-lot application, not a guaranteed result.
What is the difference between A-tail and B-head for CF PHARMTECH?
Based on the prospectus's legal application tiers, A-tail is 600 lots and B-head is 800 lots, representing about HK$4.4M and HK$5.9M of application principal. Official average allotment was 0.05 lots and 0.08 lots, versus pre-allotment model estimates of 0.07 lots and 0.11 lots. Pool A and Pool B are allocated separately, so application size alone does not show capital efficiency.
Can the grey-market price of CF PHARMTECH be treated as the listing price?
The compiled grey-market observation is about +219.0%, versus +161.0% on the listing day. Grey-market prints are pre-listing sentiment from public sources, not the official opening price.
Why does CF PHARMTECH have three reference ratings?
The current status is "Listed", so start with the post-grey section. Subscription, pre-grey and post-grey each use only the public information available at that point, so the score can change. Labels are high attention / neutral / caution only — informational comparison, not a buy or subscribe call.